Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribavirin

Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribavirin - Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribavirin

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003976

Enrollment

2000

Registered

2010-08-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis C whose HCV-RNA is >= 5.0 logIU/mL or null responder or relapser to interferon monotherapy.

Exclusion criteria

Exclusion criteria: Any contraindication to peginterferon alfa-2b + ribavirin therapy

Design outcomes

Primary

Measure	Time frame
Sustained virological response 24 weeks after the end of treatment	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactTatsuya Minami

The University of Tokyo Graduate School of Medicine Department of Gastroenterology

tminami-tky@umin.ac.jp03-3815-5411

Outcome results